Cooper Companies Inc (NYSE:COO) Director Robert S. Weiss sold 52,156 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $323.74, for a total value of $16,884,983.44. Following the completion of the sale, the director now directly owns 154,975 shares of the company’s stock, valued at $50,171,606.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of COO traded up $4.03 on Wednesday, hitting $328.12. The company’s stock had a trading volume of 250,074 shares, compared to its average volume of 347,731. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.68 and a current ratio of 1.21. Cooper Companies Inc has a fifty-two week low of $225.62 and a fifty-two week high of $329.11. The firm has a market capitalization of $15.93 billion, a PE ratio of 28.53, a P/E/G ratio of 2.45 and a beta of 0.78.
Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, May 30th. The medical device company reported $2.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.76 by $0.18. Cooper Companies had a return on equity of 17.25% and a net margin of 16.46%. The business had revenue of $654.30 million during the quarter, compared to analyst estimates of $655.00 million. During the same period in the previous year, the firm earned $2.86 EPS. Cooper Companies’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts predict that Cooper Companies Inc will post 12.24 EPS for the current fiscal year.
A number of brokerages have recently commented on COO. Wells Fargo & Co upped their price target on Cooper Companies from $325.00 to $356.00 and gave the company an “outperform” rating in a research note on Monday. Zacks Investment Research upgraded Cooper Companies from a “hold” rating to a “buy” rating and set a $336.00 price objective for the company in a research report on Friday, June 7th. Northcoast Research reiterated a “buy” rating and issued a $340.00 price objective (up from $331.00) on shares of Cooper Companies in a research report on Monday, June 3rd. Jefferies Financial Group boosted their price objective on Cooper Companies to $330.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Stephens boosted their price objective on Cooper Companies from $305.00 to $320.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. Cooper Companies presently has an average rating of “Buy” and an average price target of $315.36.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Recommended Story: Call Option Volume
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.